Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Genesis BioCapital is a venture capital firm founded in 2024 and based in Chattanooga, Tennessee. The firm focuses on creating and scaling biopharmaceutical companies that develop transformative therapies for significant unmet medical needs. Genesis BioCapital employs a dual strategy that combines company formation with growth investing, allowing them to incubate companies from scientific discovery through subsequent funding rounds.
The firm operates with a multidisciplinary team of experienced biopharma executives and fund operators, providing essential scientific, operational, and clinical expertise to its portfolio companies. Genesis BioCapital's headquarters are located at 200 West MLK Blvd. Suite 1000, PMB#3073, Chattanooga, TN 37402. The firm is positioned to leverage its expertise in the biopharmaceutical sector, particularly in precision medicine and genome engineering.
Genesis BioCapital primarily invests in seed and Series A stages, focusing on biopharmaceutical advancements. The firm incubates companies from scientific discovery and invests in subsequent funding rounds, emphasizing transformative therapies for significant unmet medical needs. Their investment strategy includes a strong focus on precision medicine and genome engineering, which are critical areas in the healthcare sector.
Genesis BioCapital seeks to identify promising scientific discoveries and build companies around them. The firm looks for founders who are deeply knowledgeable in their fields and are committed to addressing significant healthcare challenges. Their deal structure often involves active participation in the operational and clinical development of portfolio companies, ensuring that they provide substantial value beyond just capital.
Genesis BioCapital's notable portfolio company is KOMO Biosciences, which emerged from stealth in July 2024. KOMO specializes in precision genome engineering and has developed technology that enables the non-viral insertion of large genes into specific genome sites with high efficiency. This innovative approach allows for the insertion of genes ranging from 7 to 15 kb with an integration efficiency of approximately 80% per chromosome in about 96% of cells.
KOMO Biosciences was created by Genesis BioCapital, highlighting the firm's venture-builder model rather than a passive investment approach. The firm collaborates with co-investors such as LDV Partners, General Inception, and Modi Ventures to support KOMO's growth and development.
Ray Tabibiazar - Managing Partner of Genesis BioCapital. Ray has a strong background in healthcare investing and has been instrumental in the firm's strategy of combining company formation with growth investing. His expertise lies in identifying promising scientific discoveries and building companies around them.
To pitch Genesis BioCapital, founders should send an email to info@genesisbiocapital.com. It is important to include a comprehensive deck that outlines the scientific discovery, market opportunity, and the team’s qualifications. The firm prefers detailed information on the technology and its potential applications in the biopharmaceutical space.
Response times may vary, but founders should expect a thorough review process given the firm's focus on scientific rigor and transformative therapies. Warm introductions are beneficial, especially from academic or industry contacts familiar with the firm’s focus areas.
In July 2024, Genesis BioCapital announced the launch of KOMO Biosciences, which emerged from stealth following the publication of a groundbreaking precision genome engineering paper. This marked a significant milestone for the firm as it showcased their venture-builder model in action.
Genesis BioCapital continues to develop its presence in the biopharmaceutical sector, focusing on investments that align with their mission to address significant unmet medical needs.
What are Genesis BioCapital's investment criteria?
Genesis BioCapital focuses on seed and Series A investments in biopharmaceutical companies. They look for startups that are developing transformative therapies for significant unmet medical needs, particularly in precision medicine and genome engineering.
How can founders pitch to Genesis BioCapital?
Founders can reach out to Genesis BioCapital via email at info@genesisbiocapital.com. It is advisable to include a detailed overview of the scientific discovery and the potential impact of the proposed solution in the pitch.
What makes Genesis BioCapital different from other VCs?
Genesis BioCapital operates as a venture-builder, actively creating and scaling companies rather than solely investing in existing ones. Their dual strategy of company formation and growth investing allows them to provide significant operational and clinical expertise to their portfolio companies.
What is the geographic focus of Genesis BioCapital?
The firm primarily focuses on North America, particularly in regions with strong biopharmaceutical ecosystems, such as Chattanooga, Tennessee.
What is the typical check size for investments?
While specific check sizes are not disclosed, Genesis BioCapital invests primarily in seed and Series A rounds, which typically range from hundreds of thousands to several million dollars, depending on the stage and needs of the company.
What kind of support do portfolio companies receive post-investment?
Genesis BioCapital provides extensive support to its portfolio companies, including scientific, operational, and clinical expertise. Their multidisciplinary team works closely with founders to help navigate the challenges of building a biopharmaceutical company.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.